Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys Medical Discovery Institute, doing business as Sanford-Burnham Medical Research Institute, is a nonprofit biomedical research organization based in La Jolla, California, that acts as a prime recipient of federal research grants across a diverse portfolio of basic and translational life sciences research. The institute competes entirely in full-and-open federal funding, with no SBA set-aside designations, and operates as an independent research entity rather than through federal service contracts or contract vehicles.

The institute's federal footprint centers on investigator-initiated biomedical research grants funded primarily by the National Institutes of Health and the Defense Health Agency. Recent representative work spans cancer metabolism and immunotherapy, neurodegenerative disease mechanisms, aging biology, and infectious disease. A $3.86 million Cooperative Agreement from the National Institute of Neurological Disorders and Stroke (CFDA 93.279) awarded April 2026 funds neurotensin receptor 1 allosteric modulator research for pain and opioid use disorder treatment. A $1.677 million Project Grant from the National Institute of General Medical Sciences (CFDA 93.859) awarded April 2026 investigates TMEM2 cell surface hyaluronidase mechanisms in fibrosis. A $571 thousand Project Grant from the Defense Health Agency (CFDA 12.420) awarded November 2024 supports chemical engineering approaches to amyotrophic lateral sclerosis treatment, with J. David Gladstone Institutes providing surgical and tissue-processing expertise as a named subrecipient. Earlier work includes a $1.33 million grant from NASA's Shared Services Center (January 2022) on oxidative stress responses in altered gravity using Drosophila and C. elegans model organisms, and a $632 thousand NIGMS grant (July 2026) for acquisition of a Cytek Aurora CS Spectral Cell Sorter to replace aging flow cytometry equipment. The institute also received a $292.5 thousand National Heart, Lung, and Blood Institute grant (CFDA 93.837, August 2025) on microprotein discovery in hematopoiesis.

Customer concentration is heavily skewed to the National Institutes of Health system. The top five funding entities account for 68% of recent awards: the Department of Health and Human Services National Institutes of Health (275 awards), the National Cancer Institute (68 awards), the National Institute on Aging (61 awards), the Department of Defense (29 awards), and HHS itself (28 awards). By potential-value share, NASA's Shared Services Center leads with $2.5 million across six awards, followed by the National Heart, Lung, and Blood Institute with $204 thousand across 25 awards. The institute's grant portfolio shows modest year-over-year activity with 27 awards in 2022, declining to 21 in 2023, then rising to 31 in 2024 and 23 in 2025, with 9 recorded through mid-2026. Forty-five awards face ultimate completion within the next twenty-four months, representing recompete opportunity.

The institute operates as a prime recipient on 92% of awards (623 of 680 total); the remaining 8% (57) are grant sub-awards where Sanford Burnham Prebys performs research under larger consortium or multi-institutional grants. Named subrecipient relationships include the University of Pennsylvania (aging and hepatocyte cell identity research), Cedars-Sinai Medical Center (drug discovery guidance on aging and GCDH inhibitors), Beckman Research Institute of City of Hope (exercise therapy and metabolic research), Ohio State University (skeletal and dental mineralization studies), and Stanford, Columbia University, and the Salk Institute (molecular neuroscience and aging research). The institute hosts the Conrad Prebys Center for Chemical Genomics, which serves as an internal resource for high-throughput screening, medicinal chemistry, and compound optimization across its own and collaborative research programs.

Service Contract Inventory data shows minimal federal services contracting: four SCI records across FY2022–FY2024, with 9.7 FTEs in FY2022 and 2.0 FTEs in FY2024, both as named subcontractors. This figure reflects that Sanford Burnham Prebys operates primarily through investigator-initiated research grants rather than through federal service contracts.

The institute's strategic focus spans cancer biology (particularly pancreatic cancer metabolism and immunotherapy), aging and age-associated disease (Alzheimer's disease, senescence, neurodegeneration), stem cell biology, drug discovery and development, and translational medicine addressing unmet medical needs in addiction, diabetes, fibrosis, and neurological disorders. With 40 research laboratories organized around disease areas and approximately 275 awards from NIH alone, Sanford Burnham Prebys functions as a premier independent research organization anchored to federal scientific priorities, particularly in basic science that underpins translational and clinical applications for civilian health.